A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat w momencie podpisania dokumentów badania
- •Potwierdzony rozpoznaniem rak jajnika, który nie reaguje na leczenie platynę
- •Otrzymano co najmniej 1, ale nie więcej niż 4 poprzednie linie leczenia systemowego
- •Otrzymano wcześniej leczenie mirvetuximabem soravtansinem (chyba że pacjent ma przeciwwskazania)
- •Guz wykazuje pozytywny receptor folianu alfa
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (5)
GSK Investigational Site
Randwick, Australia
GSK Investigational Site
Montreal, Canada
GSK Investigational Site
Montreal, Canada
GSK Investigational Site
Hyōgo, Japan
GSK Investigational Site
Osaka, Japan
Trial contact
US GSK Clinical Trials Call Center
EU GSK Clinical Trials Call Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.